A Phase 2 interventional study of Tociliuzumab in COVID-19 Pneumonia, sponsored by Hoffmann-La Roche. Completed at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-31.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing tocilizumab in COVID-19 — 3 open to participants now, 4 under way, 2 of them phase 3. tocilizumab · COVID-19.
Among the 38 studies testing tocilizumab in COVID-19, this one is the 23rd largest by enrollment, is one of 34 that started in 2020, is one of 14 in phase 2, and was the 16th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →3 of the 38 studies testing tocilizumab in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Lebanese University · Sites in Lebanon
Ages 18+
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 14 · Phase 4 2
First in 2016; this study’s year is marked. 34 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is close to the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 150 across the 38 interventional studies. Of the 23 that completed or were terminated, 8 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 38 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 9 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 38 studies testing tocilizumab in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the pharmacodynamics, pharmacokinetics, safety and efficacy of two different doses of tocilizumab (TCZ) in combination with standard-of-care (SOC) in hospitalized adult participants with moderate to severe COVID-19 pneumonia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive intravenous (IV) tocilizumab (TCZ) at a dose of 8 mg/kg in addition to standard-of-care treatment.
Drug: Tociliuzumab
Participants will receive IV tocilizumab (TCZ) at a dose of 4 mg/kg in addition to standard-of-care treatment.
Drug: Tociliuzumab
Participants will receive IV TCZ.
Area Under the Curve From Day 0-28 (AUC0-d28) of Tocilizumab)
Time frame: Days 0-28. Participants received a second dose within 8-24 hours after the initial infusion of TCZ at the discretion of the investigator upon clinically significant demonstration of worsening signs or symptoms.
Maximum Serum Concentration (Cmax) of Tocilizumab
Time frame: Baseline - Day 60. Participants received a second dose within 8-24 hours after the initial infusion of TCZ at the discretion of the investigator upon clinically significant demonstration of worsening signs or symptoms.
Clearance (CL) of Tocilizumab
Time frame: Baseline - Day 60. Participants received a second dose within 8-24 hours after the initial infusion of TCZ at the discretion of the investigator upon clinically significant demonstration of worsening signs or symptoms.
Volume of the Central Compartment (Vc) of Tocilizumab
Time frame: Baseline - Day 60. Participants received a second dose within 8-24 hours after the initial infusion of TCZ at the discretion of the investigator upon clinically significant demonstration of worsening signs or symptoms.
Serum Concentration of C-reactive Protein (CRP) Following Administration of IV TCZ
Time frame: Baseline - Day 60
Serum Concentration of Ferritin Following Administration of IV TCZ
Time frame: Baseline - Day 60
Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of IV TCZ
Time frame: Baseline - Day 60
Serum Concentration of Interleukin-6 (IL-6) Following Administration of IV TCZ
Time frame: Baseline - Day 60
Pecentage of Participants With Adverse Events
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Up to Day 60
Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time
Time frame: Baseline - Day 60
Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity
Time to Real-Time Polymerase Chain Reaction (RT-PCR) virus negativity was defined as the number of days from the first dose of study drug to when a negative RT-PCR SARS-CoV-2 assessment result was observed. Results are presented as a cumulative incidence function (CIF) with death as a competing risk.
Time frame: Up to Day 28
Proportion of Participants With Any Post-Treatment Infection
Time frame: Up to Day 60
| Milestone | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| Started | 49 | 48 |
| Completed | 30 | 35 |
| Not completed | 19 | 13 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 10 | 7 |
| Withdrew: Death | 8 | 6 |
| µg/mL*day | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| One dose | 371 (196 to 1040) | 849 (471 to 1500) |
| Two doses | 837 (592 to 1480) | 1330 (1130 to 1810) |
| µg/mL | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| One dose | 82.2 (48.8 to 134) | 159 (101 to 234) |
| Two doses | 150 (110 to 203) | 228 (198 to 363) |
| L/day | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| One dose | 0.451 (0.261 to 0.697) | 0.487 (0.179 to 1.16) |
| Two doses | 0.468 (0.327 to 0.701) | 0.629 (0.376 to 1.02) |
| L | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| One dose | 4.14 (2.47 to 7.11) | 4.34 (3.08 to 7.88) |
| Two doses | 4.2 (2.54 to 5.17) | 4.57 (3.59 to 7.27) |
| mg/L | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| Baseline | 125.04 ± 121.5 | 115.77 ± 128.7 |
| Day 1 - 15 min post-dose | 124.67 ± 118.8 | 109.19 ± 134.4 |
| Day 1 - pre-dose 2nd infusion | 123.49 ± 68.0 | 118.83 ± 45.1 |
| Day 1 - 15 min post-dose 2nd infusion | 116.89 ± 62.4 | 112.97 ± 53.4 |
| Day 2 - 24 hours post-dose | 85.75 ± 133.1 | 86.01 ± 124.2 |
| Day 3 | 41.56 ± 129.6 | 39.17 ± 134.8 |
| Day 7 | 7.27 ± 145.1 | 5.62 ± 188.3 |
| Day 14 | 4.42 ± 554.8 | 0.87 ± 95.0 |
| Day 21 | 3.73 ± 552.5 | 1.75 ± 1681.6 |
| Day 28 | 3.01 ± 483.0 | 2.57 ± 2251.1 |
| Day 35 | 2.12 ± 234.5 | 11.25 ± 1543.9 |
| Day 60 | 2.41 ± 256.0 | 1.61 ± 154.1 |
| pmol/L | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| Baseline | 2081.46 ± 162.4 | 1821.19 ± 174.0 |
| Day 2 - 24 hours post-dose | 2282.62 ± 191.3 | 1938.19 ± 154.6 |
| Day 3 | 2016.10 ± 128.0 | 2060.41 ± 131.2 |
| Day 7 | 1760.82 ± 170.3 | 1494.76 ± 86.7 |
| Day 14 | 1108.34 ± 127.2 | 720.66 ± 102.3 |
| Day 21 | 754.24 ± 138.4 | 558.57 ± 119.0 |
| Day 28 | 393.46 ± 139.3 | 519.51 ± 139.0 |
| Day 35 | 309.23 ± 105.5 | 291.24 ± 66.5 |
| Day 60 | 282.85 ± 148.7 | 246.17 ± 171.4 |
| ng/L | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| Baseline | 35869.87 ± 29.1 | 35331.04 ± 31.3 |
| Day 1 - 15 min post-dose | 47037.59 ± 56.1 | 40928.43 ± 46.4 |
| Day 2 - 15 min post-dose | 80880.16 ± 24.9 | 44300.00 ± NA |
| Day 2 - 24 hours post-dose | 97280.14 ± 31.3 | 90057.53 ± 28.8 |
| Day 3 | 139128.70 ± 26.5 | 139528.82 ± 30.3 |
| Day 7 | 261637.28 ± 30.2 | 263899.86 ± 26.7 |
| Day 14 | 258484.08 ± 52.3 | 339661.18 ± 19.6 |
| Day 21 | 162025.68 ± 73.1 | 265981.84 ± 49.1 |
| Day 28 | 82508.76 ± 102.6 | 162795.31 ± 106.0 |
| Day 35 | 80425.91 ± 138.7 | 144868.00 ± 105.4 |
| Day 60 | 36049.91 ± 21.7 | 34258.34 ± 22.2 |
| ng/L | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| Day 1 - 15 min post-dose | 336.99 ± 248.8 | 325.96 ± 236.4 |
| Day 2 - 15 min post-dose | 292.69 ± 159.8 | 638.00 ± NA |
| Day 2 - 24 hours post-dose | 733.99 ± 226.5 | 757.17 ± 172.4 |
| Day 3 | 748.82 ± 394.2 | 743.84 ± 263.0 |
| Day 7 | 545.44 ± 315.9 | 589.21 ± 429.0 |
| Day 14 | 234.88 ± 332.2 | 125.64 ± 345.9 |
| Day 21 | 49.16 ± 482.7 | 91.86 ± 465.9 |
| Day 28 | 5.73 ± NA | 28.66 ± 371.7 |
| Day 35 | 7.68 ± 361.9 | 39.79 ± 503.0 |
| Day 60 | 2.52 ± NA | 2.28 ± NA |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| Percentage of Participants | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| Pecentage of Participants With Adverse Events | 57.1 | 45.8 |
| copies/µL | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| Baseline | 30.56 (0.1 to 14458.9) | 8.51 (0.1 to 132429.0) |
| Day 2 | 8.38 (0.1 to 6328.1) | 7.90 (0.1 to 264252.7) |
| Day 3 | 3.82 (0.1 to 338006.1) | 4.46 (0.1 to 135875.7) |
| Day 4 | 2.44 (0.1 to 17142.1) | 2.73 (0.1 to 159013.2) |
| Day 5 | 8.74 (0.1 to 2930.4) | 5.39 (0.1 to 59216.3) |
| Day 6 | 0.91 (0.1 to 41683.2) | 2.56 (0.1 to 13318.7) |
| Day 7 | 0.49 (0.1 to 11609.3) | 1.47 (0.1 to 14185.5) |
| Day 10 | 2.56 (0.1 to 149.3) | 0.59 (0.1 to 556.2) |
| Day 14 | 0.14 (0.1 to 26.5) | 0.18 (0.1 to 436.5) |
| Day 21 | 0.1 (0.1 to 39.6) | 0.12 (0.1 to 56.4) |
| Day 28 | 0.16 (0.1 to 3.6) | 0.12 (0.1 to 3.4) |
| Day 35 | 0.1 (0.1 to 0.2) | 0.12 (0.1 to 5.6) |
| Day 45 | 0.1 (0.1 to 0.1) | 0.1 (0.1 to 0.1) |
| Early withdrawal | — | 0.1 (0.1 to 0.1) |
| Day 60 | 0.1 (0.1 to 0.1) | 0.1 (0.1 to 0.3) |
Time to Real-Time Polymerase Chain Reaction (RT-PCR) virus negativity was defined as the number of days from the first dose of study drug to when a negative RT-PCR SARS-CoV-2 assessment result was observed. Results are presented as a cumulative incidence function (CIF) with death as a competing risk.
| Probability | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| CIF for event on Day 7 | 0.3389 | 0.2874 |
| CIF for death on Day 7 | 0.0665 | 0.0000 |
| CIF for event on Day 14 | 0.5068 | 0.5727 |
| CIF for death on Day 14 | 0.1024 | 0.0884 |
| CIF for event on Day 21 | 0.5068 | 0.5727 |
| CIF for death on Day 21 | 0.1497 | 0.1280 |
| CIF for event on Day 28 | 0.5730 | 0.6327 |
| CIF for death on Day 28 | 0.3420 | 0.1793 |
| Percentage of Participants | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| COVID-19 pneumonia | 6.1 | 2.1 |
| Sepsis | 2.0 | 4.2 |
| Septic shock | 2.0 | 4.2 |
| Pneumonia | 2.0 | 2.1 |
| Urinary tract infection | 2.0 | 2.1 |
| Abscess limb | 2.0 | 0 |
| Atypical pneumonia | 2.0 | 0 |
| Pneumonia bacterial | 2.0 | 0 |
| Pneumonia klebsiella | 2.0 | 0 |
| Pneumonia streptococcal | 2.0 | 0 |
| Staphylococcal infection | 2.0 | 0 |
Collected over Up to Day 60. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TCZ 4 mg/kg | 8/49 (16.3%) | 15/49 (30.6%) | 4/49 (8.2%) |
| TCZ 8 mg/kg | 6/48 (12.5%) | 12/48 (25%) | 3/48 (6.3%) |
| Event | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 1/49 | 4/48 |
| COVID-19 pneumoniaInfections and infestations | 3/49 | 1/48 |
| Septic shockInfections and infestations | 1/49 | 2/48 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/49 | 2/48 |
| DiarrhoeaGastrointestinal disorders | 2/49 | 0/48 |
| Failure to thriveMetabolism and nutrition disorders | 2/49 | 0/48 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 0/49 | 1/48 |
| Cardiac failure congestiveCardiac disorders | 0/49 | 1/48 |
| Cardiogenic shockCardiac disorders | 0/49 | 1/48 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/49 | 1/48 |
| Event | TCZ 4 mg/kg | TCZ 8 mg/kg |
|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 1/49 | 3/48 |
| Alanine aminotransferase increasedInvestigations | 3/49 | 0/48 |
| Aspartate aminotransferase increasedInvestigations | 3/49 | 0/48 |
| Age, Continuous(Years) | TCZ 4 mg/kg | TCZ 8 mg/kg | Total |
|---|---|---|---|
| Mean | 56.8 ± 14.3 | 59.8 ± 14.6 | 58.3 ± 14.4 |
| Sex: Female, Male(Participants) | TCZ 4 mg/kg | TCZ 8 mg/kg | Total |
|---|---|---|---|
| Female | 22 | 18 | 40 |
| Male | 27 | 30 | 57 |
| Ethnicity (NIH/OMB)(Participants) | TCZ 4 mg/kg | TCZ 8 mg/kg | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 15 | 26 |
| Not Hispanic or Latino | 35 | 32 | 67 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Race (NIH/OMB)(Participants) | TCZ 4 mg/kg | TCZ 8 mg/kg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 20 | 13 | 33 |
| White | 15 | 23 | 38 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 8 | 9 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from May 2020 to primary completion in Aug 2020, 3 months.
Results were first posted in Aug 2021, 1 year after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 3 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab